Exactly my point. Biotech usually takes 10 years to get to market. This, nor can any company, let alone one with 5 people, fulfill our voracious appetite for information. The man hours used in posting questions here probably exceeds the man hours being used to do actual viricide research at this point.
As I said before, in my opinion as a long term biotech investor and VC professional, the market cap is still too high for where we are. It may well blow the doors off, but it is not worth the price until there is some legitimate published data from a reputable US source. Then, if it works, hold on. I am a long but I will average up as the story unfolds and not over invest until I figure out whether the technology works or whether it is a false positive (or even a fraud??) frankly.
Two things concern me at this point on the published data. Why did the viricide for rabies only save 30% of the dogs in Vietnam (and not 90%), and why did I read somewhere that Dr S said that when attaching Ebola, the virus secreted some kind of compound that effectively counteracted the viricide and reduced its effectiveness? Also what is the scoop on Seaside? For a company with a $200MM market cap to raise a measly $5MM and do it with a toxic convertable preferred (where the buyer can sell into the market to increase their conversion ration by driving down the price) beats me - why didn't they just sell another couple of million common into the market on a spot trade???? These kinds of financings are usually done by companies with serious issues.
Viruses have been around for at least 5 billion years. They are pretty smart. We are only just figuring out what they do so this will not be a slam dunk. However, we are at the start of a megatrend that will probably change medicine as we know it. Whether or not it is this company we cannot know yet. I am long but have low short term expectations. These companies are like marathons, not sprints. Just look at Dendreon.
AI
Market Data 
Markets 
